Investigation of the performance of Gas6 plasma level as predictor of disease severity, thromboembolism occurrence and mortality in patients with COVID-19
Prof. Anne Angelillo-Scherrer, Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital. Hematology Research Group, Department for Biomedical Research, University of Bern. For more information, please visit the website.
COVID-19 patients often develop inflammation throughout the whole body and a tendency to clot, leading to an increased risk of thromboembolism and a poor evolution. Identification of biomarkers to assist physicians treating COVID-19 patients in risk stratification and decision-making processes is needed. Growth arrest-specific gene 6 (Gas6) might be a candidate biomarker because of its role in both inflammation and blood clotting. Here, we aim at assessing the performance of Gas6 as predictor of disease severity, thromboembolism occurrence and mortality in patients with COVID-19. Therefore, we will conduct a retrospective in 600 patients and a prospective study in 50-150 patients.